Aston Science Announces Phase 1 Clinical Trial Results of Breast Cancer Therapeutic Vaccine 'AST-302'

[Asia Economy Reporter Lee Gwan-joo] Aston Science announced on the 7th that it presented the Phase 1 clinical trial results of the cancer treatment vaccine 'AST-302' for breast cancer at the 'San Antonio Breast Cancer Symposium (SABCS)' held in Texas, USA.

This year marks the 45th SABCS, considered the world's largest international breast cancer conference. It is hosted by the American Association for Cancer Research (AACR) and UT Health San Antonio’s Mays Cancer Center, with over 10,000 researchers worldwide participating.

At this conference, Professor Mary L. Disis, chief of the Cancer Vaccine Research Institute at the University of Washington and a co-researcher at Aston Science, presented the Phase 1 clinical trial results of Aston Science's AST-302 drug.

The Phase 1 clinical trial was conducted to confirm the safety, tolerability, and immunogenicity of the multi-antigen vaccine AST-302 targeting HER2, IGFBP-2, and IGF-IR antigens in patients with non-metastatic breast cancer. The trial involved patient groups receiving three different dosages.

According to the presentation, the group receiving the medium dose of 300mcg showed the highest antigen-specific immunity (80%), and drug-related adverse reactions were mild, Grade 1/2, such as injection site reactions or fatigue, similar to existing cancer vaccines. Currently, a Phase 2 clinical trial is underway combining the drug with standard treatment as a neoadjuvant therapy for patients with HER2-positive breast cancer before surgery.

Jeong Eun-kyo, Chief Medical Officer (CMO) of Aston Science, stated, "Based on the immunogenicity and safety data obtained from this Phase 1 trial for doses applicable to later-stage clinical trials, we plan to expand and continue cancer treatment vaccine research for breast cancer."

This content was produced with the assistance of AI translation services.